ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Inspire Corporate Bond ETF
24.19
-0.0200
-0.08%
盤後：
24.19
0.0000
0.00%
16:10 EST
成交量：
5.15萬
成交額：
124.59萬
市值：
4.79億
市盈率：
- -
高：
24.28
開：
24.17
低：
24.17
收：
24.21
52周最高：
24.85
52周最低：
22.84
股本：
1,980.00萬
流通股本：
1,980.00萬
量比：
0.93
換手率：
0.26%
股息：
1.02
股息率：
4.20%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准
智通财经
·
02/24
釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?
智通财经网
·
02/05
Vivosim Labs, Inc.盤中異動 大幅下跌8.35%
市场透视
·
01/09
60億美元豪賭見效！武田自免口服新藥針對中重度斑塊狀銀屑病3期數據積極，擬明年向FDA提交上市申請
蓝鲸财经
·
2025/12/19
中信證券：新老管線數據讀出頻現 MNC加速IBD領域佈局
智通财经
·
2025/12/11
顯著降低克羅恩病用藥負擔，利生奇珠單抗納入新版國家醫保目錄
上观新闻
·
2025/12/08
Vivosim Labs, Inc.盤中異動 早盤股價大漲7.31%
市场透视
·
2025/11/28
Vivosim Labs, Inc.盤中異動 下午盤股價大漲5.29%
市场透视
·
2025/11/12
Spyre Therapeutics宣佈授予員工股票期權激勵獎勵
投资观察
·
2025/10/04
羅氏(RHHBY.US)4億美元加碼IBD領域 開發臨床前口服小分子
智通财经
·
2025/09/02
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.19,"timestamp":1772053200000,"preClose":24.21,"halted":0,"volume":51512,"hourTrading":{"tag":"盘后","latestPrice":24.19,"preClose":24.19,"latestTime":"16:10 EST","volume":10,"amount":241.9,"timestamp":1772053804182,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0008261049153242286,"floatShares":19800000,"shares":19800000,"eps":0,"marketStatus":"未開盤","change":-0.02,"latestTime":"02-25 16:00:00 EST","open":24.17,"high":24.277,"low":24.17,"amount":1245874.4268,"amplitude":0.00442,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.21,"sharesOutstanding":19800000,"nav":24.18,"aum":478802924.01,"dividendRate":0.042001,"bidAskSpread":0.00124,"preHourTrading":{"tag":"盘前","latestPrice":24.21,"preClose":24.21,"latestTime":"08:47 EST","volume":1,"amount":24.21,"timestamp":1772027225597,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.19,"preClose":24.19,"latestTime":"16:10 EST","volume":10,"amount":241.9,"timestamp":1772053804182,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.926658},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":19800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.926658,"shares":19800000,"dividePrice":1.016,"high":24.277,"amplitude":0.00442,"preClose":24.21,"low":24.17,"week52Low":22.84,"pbRate":"--","week52High":24.85,"institutionHeld":0,"latestPrice":24.19,"eps":0,"divideRate":0.042001,"volume":51512,"delay":0,"ttmEps":0,"open":24.17,"prevYearClose":24.2,"prevWeekClose":24.22,"prevMonthClose":24.15,"prevQuarterClose":24.2,"fiveDayClose":24.26,"twentyDayClose":24.21,"sixtyDayClose":24.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-02-24","symbol":"IBD","amount":0.0779,"announcedDate":"2026-02-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-24","defaultRemindTime":1771943400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-02","payableDate":"2026-02-24","currency":"USD","dateTimestamp":1771909200000,"payDate":"2026-03-02"},{"date":"2026-01-27","symbol":"IBD","amount":0.0592,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-02-02"},{"date":"2025-12-17","symbol":"IBD","amount":0.121,"announcedDate":"2025-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-17","defaultRemindTime":1765981800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-17","currency":"USD","dateTimestamp":1765947600000,"payDate":"2025-12-24"},{"date":"2025-11-21","symbol":"IBD","amount":0.0729,"announcedDate":"2025-11-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-21","defaultRemindTime":1763735400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-26","payableDate":"2025-11-21","currency":"USD","dateTimestamp":1763701200000,"payDate":"2025-11-26"},{"date":"2025-10-28","symbol":"IBD","amount":0.0824,"announcedDate":"2025-10-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-28","defaultRemindTime":1761658200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-03","payableDate":"2025-10-28","currency":"USD","dateTimestamp":1761624000000,"payDate":"2025-11-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613717630","title":"中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717630?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","BK1574","IBD","03681"],"gpt_icon":0},{"id":"2609432256","title":"釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432256","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609432256?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 16:35","pubTimestamp":1770280559,"startTime":"0","endTime":"0","summary":"近期，英硅智能(03696)宣布提名靶向NLRP3的外周限制性抑制剂ISM5059，该候选药物具有新颖母核，由英硅智能自有Pharma.AI平台驱动设计。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["PD","BBB","AD","IBD","LU1169589451.USD","LU1169590202.USD","CNS","BK4135","BK4132","BK4023"],"gpt_icon":0},{"id":"2602122803","title":"Vivosim Labs, Inc.盤中異動 大幅下跌8.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602122803?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 01:55","pubTimestamp":1767894943,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日01时55分，Vivosim Labs, Inc.股票出现异动，股价大幅下挫8.35%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","VIVS"],"gpt_icon":0},{"id":"2592755154","title":"60億美元豪賭見效！武田自免口服新藥針對中重度斑塊狀銀屑病3期數據積極，擬明年向FDA提交上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2592755154","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592755154?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 16:36","pubTimestamp":1766133370,"startTime":"0","endTime":"0","summary":"近日，武田宣布其针对中重度斑块状银屑病成人患者的新一代、高选择性口服酪氨酸激酶2抑制剂Zasocitinib在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极的主要结果。据悉，武田制药计划在即将举行的医学会议上公布研究数据，并计划自2026财年向美国食品药品监督管理局及其他监管机构递交新药上市申请。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766128980838994392","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBD","BMS"],"gpt_icon":0},{"id":"2590550876","title":"中信證券：新老管線數據讀出頻現 MNC加速IBD領域佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590550876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590550876?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 09:34","pubTimestamp":1765416866,"startTime":"0","endTime":"0","summary":"MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角。MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角作为自身免疫疾病领域中，患者人数众多且当前一年维持期疗效仍仅有30%-50%临床缓解率的适应症，IBD吸引了众多MNC布局。根据过往交易规模以及MNC对产品峰值的预期，该行预计一项临床阶段的优质IBD资产的交易对价在20亿美金以上。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1255011170.USD","LU1655091616.SGD","LU0405327148.USD","LU1794554557.SGD","IBD","BK0276","LU1064130708.USD","LU2289578879.USD","LU1997245177.USD","BK0196","BK0028","LU1997244956.HKD","06030","BK0188","LU1064131003.USD","600030","LU1720050803.USD","BK1564","BK0012","BK0183","BK1516","LU2148510915.USD","LU2495084118.USD","LU1997245094.SGD","LU1328615791.USD","BK1521","BK1147","LU0405327494.USD"],"gpt_icon":0},{"id":"2589216380","title":"顯著降低克羅恩病用藥負擔，利生奇珠單抗納入新版國家醫保目錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2589216380","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589216380?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 15:56","pubTimestamp":1765180571,"startTime":"0","endTime":"0","summary":"12月7日，《国家基本医疗保险、工伤保险和生育保险药品目录（2025年版）》（以下简称“医保目录”）正式公布，全球生物医药公司艾伯维旗下靶向创新药物利生奇珠单抗注射液（喜开悦?）位列其中。该药物在获批上市当年即被纳入医保，充分体现了其临床价值与国家医保政策对创新疗法的支持力度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585275052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4566","IE00BFMHRM44.USD","BK4023","BK4543","NICE","IBD"],"gpt_icon":0},{"id":"2587075284","title":"Vivosim Labs, Inc.盤中異動 早盤股價大漲7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587075284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587075284?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 22:33","pubTimestamp":1764340392,"startTime":"0","endTime":"0","summary":"北京时间2025年11月28日22时33分，Vivosim Labs, Inc.股票出现波动，股价大幅上涨7.31%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIVS","BK4139","IBD"],"gpt_icon":0},{"id":"2582329246","title":"Vivosim Labs, Inc.盤中異動 下午盤股價大漲5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582329246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582329246?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 03:13","pubTimestamp":1762888437,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日03时13分，Vivosim Labs, Inc.股票出现异动，股价快速拉升5.29%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体涨幅为1.47%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111203135797630a06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111203135797630a06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","VIVS"],"gpt_icon":0},{"id":"1195222682","title":"Spyre Therapeutics宣佈授予員工股票期權激勵獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=1195222682","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195222682?lang=zh_tw&edition=fundamental","pubTime":"2025-10-04 04:08","pubTimestamp":1759522131,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2025年10月3日——临床阶段生物技术公司Spyre Therapeutics, Inc.今日宣布，公司独立董事会薪酬委员会批准向三名非执行员工授予总计42,500股普通股的股票期权，作为根据经修订的《Spyre Therapeutics, Inc. 2018年股权激励计划》项下的股权激励奖励。Spyre Therapeutics是一家临床阶段生物技术公司，致力于通过结合一流的抗体工程、剂量优化和合理的治疗组合，开发下一代炎症性肠病和其他免疫介导疾病产品。Spyre的产品管线包括针对α4β7、TL1A和IL-23的研究性延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","IBD","NQmain","SYRE","BK4007"],"gpt_icon":0},{"id":"2564007528","title":"羅氏(RHHBY.US)4億美元加碼IBD領域 開發臨床前口服小分子","url":"https://stock-news.laohu8.com/highlight/detail?id=2564007528","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564007528?lang=zh_tw&edition=fundamental","pubTime":"2025-09-02 21:15","pubTimestamp":1756818907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团成员基因泰克达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病的临床前口服小分子项目。根据协议条款，OMass将获得2000万美元的首付款，此外还有可能获得超过4亿美元的潜在临床前、开发、商业和净销售额里程碑付款。在此合作下，OMass将主导该项目的初步临床前开发，直至候选化合物选定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBD","RHHBY","BK4007","03165"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}